Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
- Published In:
- Biomedicines, 13(7) (2025)
- Database ID:
- RPEP-10489
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10489APA
Chrysavgis, Lampros; Mourelatou, Niki-Gerasimoula; Cholongitas, Evangelos. (2025). Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?. Biomedicines, 13(7). https://doi.org/10.3390/biomedicines13071516
MLA
Chrysavgis, Lampros, et al. "Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?." Biomedicines, 2025. https://doi.org/10.3390/biomedicines13071516
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan..." RPEP-10489. Retrieved from https://rethinkpeptides.com/research/chrysavgis-2025-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.